Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 1:53 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–480 of 3,236 matching trials from the live ClinicalTrials.gov search.

Filters: Not yet recruiting Clear all

Conditions: Wound Heal
Interventions: Amnion Membrane Powder, Standard of Care; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: HEPATITIS C (HCV), Opioid Use Disorder, Substance Use Disorder (SUD), Drug Use Disorders, Healthcare Access, Harm Reduction
Interventions: Partner navigation intervention booster session; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Stroke
Interventions: High intensity gait training in Movement Amplification Environment, High intensity gait training in natural environment; Other
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Opioid Use Disorder
Interventions: Recovery Community Center Linkage (RCCL), Control Condition (CC); Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 145 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hospital Inpatients
Interventions: Not listed
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Cannabis Use, Tobacco, Biomarkers
Interventions: Cannabis (THC), Tobacco Cigarette; Drug
Lead sponsor: Hannah Harris; Other
Eligibility: 18 Years to 55 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Mobility Impairment
Interventions: Use of GEL BALL FITTED MODULAR CUSHION, Use of SQUISHINS FITTED MODULAR CUSHION; Device
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2029
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Diabetes, Kidney Disease, Vascular Disease, Retinopathy
Interventions: Montelukast, Placebo; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 80 Years
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Sleep
Interventions: Construction Virtual Reality Stress Challenges, No Construction Virtual Reality Stress Challenges; Other
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 21 Years to 49 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: PTSD - Post Traumatic Stress Disorder, Insomnia, TBI (Traumatic Brain Injury)
Interventions: Suvorexant, Placebo, Prolonged Exposure Therapy for Primary Care (PE-PC); Drug · Behavioral
Lead sponsor: Northern California Institute of Research and Education; Other
Eligibility: 18 Years to 75 Years
Enrollment: 142 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: San Francisco, California

Conditions: TNBC - Triple-Negative Breast Cancer, Breast Cancer
Interventions: Pembrolizumab, Radiotherapy, Axatilimab; Drug · Radiation
Lead sponsor: Stephen Shiao; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Anesthesia
Interventions: Dexmedetomidine, General Anesthesia (control group); Drug
Lead sponsor: Soroush Merchant; Other
Eligibility: 3 Years to 6 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Soft Tissue Sarcoma
Interventions: Not listed
Lead sponsor: Power Life Sciences Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Recurrent Nodal Marginal Zone Lymphoma, Recurrent Splenic Marginal Zone Lymphoma, Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Refractory Nodal Marginal Zone Lymphoma, Refractory Splenic Marginal Zone Lymphoma
Interventions: Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Mosunetuzumab, Polatuzumab Vedotin, Positron Emission Tomography, Survey Administration, Zanubrutinib; Procedure · Biological · Drug + 1 more
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2035
U.S. locations: 14
States / cities: Newark, Delaware • Coeur d'Alene, Idaho • Post Falls, Idaho + 10 more

Conditions: Alcohol Misuse, Sexual Assault
Interventions: Positive Change© for Sailors; Behavioral
Lead sponsor: Naval Health Research Center; Federal
Eligibility: 18 Years to 24 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 4
States / cities: Tempe, Arizona • San Diego, California • Atlanta, Georgia + 1 more

Conditions: Schizophrenia / Schizoaffective Disorder
Interventions: NST-SPARK; Device
Lead sponsor: North Shore Therapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 2
States / cities: Glen Oaks, New York • Philadelphia, Pennsylvania

Conditions: Suicide, Mental Health Stigma
Interventions: RESTEPS; Behavioral
Lead sponsor: Butler Hospital; Other
Eligibility: 15 Years to 25 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Proliferative Diabetic Retinopathy, Diabetic Retinopathy, Diabetes
Interventions: PDS Implant filled with 100 mg/mL Ranibizumab, Ranibizumab; Device · Drug
Lead sponsor: Southeast Retina Center, Georgia; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Augusta, Georgia

Conditions: Prostate Cancer
Interventions: dMD-002, Control; Device · Other
Lead sponsor: Mochida Medical USA, Inc.; Industry
Eligibility: 40 Years to 74 Years · Male only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Cardiometabolic Risk Factors, Mental Health
Interventions: Not listed
Lead sponsor: National Institute of Environmental Health Sciences (NIEHS); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Cigarette Smoking-Related Carcinoma
Interventions: QuitBot Smoking Cessation Chatbot Program, QuitBot Smoking Cessation Text Messaging Program, Survey Administration, Interview, Carbon Monoxide Measurement; Device · Other · Procedure
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 772 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Post-Cardiac Arrest Syndrome
Interventions: Xenon; Combination Product
Lead sponsor: Invero Pharma, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 1,436 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 8
States / cities: Hartford, Connecticut • Gainesville, Florida • Gulfport, Mississippi + 5 more

Conditions: Asthma (Diagnosis)
Interventions: ADO-5030; Drug
Lead sponsor: Adovate; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Alcohol
Interventions: Alcohol Cancer Warning Labels; Behavioral
Lead sponsor: University of Miami; Other
Eligibility: 21 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Miami, Florida

Search by objective public record fields.

Amnion Membrane Powder Mohs Study

Pilot Study of an Adapted Partner Navigation Intervention Booster Session for Sustained Healthcare Engagement Among People Who Inject Drugs

Stroke Training to Advance Balance During Locomotor Experiences (STABLE) Trial

Enhancing Recovery Capital Amid Opioid Use Disorder Pharmacotherapy: A Pilot Randomized Trial

Behavioral Emergency Response Team (BERT) QI Project

Lung Health and Breath Biomarkers: Acute Effects of Inhaled Cannabis

User Evaluation of Advanced Personalized Modular Pressure Relief Seating Cushion Systems

MIRACLE-T2D Montelukast Intervention for Renal, Cardiovascular and Eye Health in Type 2 Diabetes

Assessing Construction Execution Under Sleep Impairment

Suvorexant 3 - PE-PC

ASTRAEA: ReinvigorAting ReSponse To ImmunotheRApy in MEtAstatic TNBC With Combination Myeloid Inhibition and Radiation

Oral Dexmedetomidine in Pediatric MRI

Investigative Analysis of Soft Tissue Sarcoma Clinical Trials: An Observational Study

Testing Mosunetuzumab Alone, With Zanubrutinib, or With Polatuzumab Vedotin for Treating Marginal Zone Lymphoma That Came Back or Didn't Get Better With Treatment

Positive Change for Sailors

NST-SPARK Open-Label Phase 1 STTR (IGNITE)

Reducing Stigma - A Treatment for Early Psychosis to Prevent Suicide

Continuous Delivery of Ranibizumab Via the Port Delivery System for Proliferative Diabetic Retinopathy-related Vitreous Hemorrhage With Pars Plana Vitrectomy and Limited PRP.

dMD-002 Pilot Study in Patients With Cavernous Nerve Injury Following Radical Prostatectomy

A Natural History of Cardiometabolic Disease Among US Bhutanese: Developing the Cross-Sectional Bhutanese Community of Central Ohio Health Study to Understand Acculturation as Synergizing Socioenvironmental and Biobehavioral Risk Factors Propagating ...

A Smartphone Application (QuitBot) for the Improvement of Smoking Cessation Among American Indians and Alaska Natives, NAITIVE Trial

Xenon for Neuroprotection During Post-Cardiac Arrest Syndrome in Comatose Survivors of an Out of Hospital Cardiac Arrest

ADO-5030 in Bronchoconstriction Challenge, Phase 1b

Eye-Tracking Alcohol Warning